Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Much Will The Pneumonia Therapeutics Market Be Worth By 2029?

The market for pneumonia therapeutics has seen significant growth in the past years. The market size will surge from $10.35 billion in 2024 to a substantial $11.46 billion in 2025, marking a compound annual growth rate (CAGR) of 10.7%. This remarkable growth during the historical period can be attributed to a rise in cases of drug-resistant strains, increased awareness about preventing pneumonia, the growth of the elderly population and those with compromised immunity, expansion of vaccination programs, and advancements in healthcare infrastructure.

The market size of pneumonia therapeutics is projected to experience a swift expansion in the upcoming years. It is forecasted to reach a value of $17.11 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.6%. This growth during the forecast period is largely facilitated by the rise in antibiotic-resistant strains, increased incidences of pneumonia in the elderly, the growth of telemedicine promoting early detection, burgeoning health care costs in evolving markets, an uptick in funds allocated for infectious disease studies, and amplified awareness campaigns. Notable trends expected during this period encompass the evolution of monoclonal antibodies, the integration of inhalable antibiotics, breakthroughs in mRNA-based vaccines, AI-powered diagnostic instruments, the employment of host-targeted therapies, pioneering immunomodulators and advancements in swift point-of-care diagnostic systems.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21258&type=smp

What Market Forces Are Contributing To The Growth Of The Pneumonia Therapeutics Market?

The anticipated increase in pneumonia cases is predicted to propel the pneumonia therapeutics market. Pneumonia is a lung infection that inflames the air sacs and induces symptoms like cough, fever, and breathing difficulties. The rise in pneumonia cases is linked to various aspects like ageing demographics, air contamination, smoking, compromised immune systems, antimicrobial resistance, and the propagation of respiratory illnesses such as COVID-19 or the flu. Treatments for pneumonia aim to fight the source of the infection, be it bacteria, viruses, or fungi, using appropriate medicines along with aiding recovery with oxygen therapy, anti-inflammatory medication, and symptom management. For example, the National Center for Biotechnology Information, a US government agency, revealed in January 2023 that pneumonia affects roughly 120 million people globally per year, resulting in about 1.3 million deaths. Almost 80% of pneumonia-related fatalities in children occur in under 2-year-olds in emerging countries. Hence, the growing occurrence of pneumonia is propelling the growth of the pneumonia therapeutics market.

Which Segments Define The Structure Of The Pneumonia Therapeutics Market?

The pneumonia therapeuticsmarket covered in this report is segmented –

1) By Product: Drugs; Vaccine; Oxygen Therapy

2) By Infection: Hospital-Acquired Pneumonia (HAP); Community-Acquired Pneumonia (CAP); Ventilator-Associated Pneumonia (VAP)

3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration

4) By End Use: Hospitals; Homecare; Specialty Clinics; Other End Users

Subsegments:

1) By Drugs: Antibiotics; Antiviral Drugs; Antifungal Drugs; Corticosteroids; Other Drugs

2) By Vaccine: Pneumococcal Vaccines; Haemophilus Influenzae Type B (Hib) Vaccines; Influenza Vaccines; Other Vaccines

3) By Oxygen Therapy: High-Flow Nasal Cannula (HFNC); Non-Invasive Ventilation (NIV); Mechanical Ventilation; Other Oxygen Therapies

Which Long-Term Trends Will Play A Crucial Role In The Pneumonia Therapeutics Market?

Major companies in the pneumonia therapeutics market are developing innovative drug formulations and treatments like antibiotic drugs to combat antibiotic resistance and improve patient outcomes. Antibiotics are medications designed to treat bacterial infections. For example, in June 2024, Orchid Pharma Limited partnered with Cipla Limited, both India-based pharmaceutical companies, to launch cefepime-enmetazobactam. This antibiotic combination treats complex infections, including UTIs and pneumonia, especially those resistant to other drugs. It helps overcome bacterial resistance, ensuring effective treatment while reducing the need for stronger antibiotics.

Which Firms Are Making The Biggest Impact In The Pneumonia Therapeutics Market?

Major companies operating in the pneumonia therapeutics market are Pfizer Inc., Roche AG, Merck & Co. Inc., AbbVie Inc, Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Shionogi & Co. Ltd, Lupin Limited, Swedish Orphan Biovitrum AB, Nabriva Therapeutics plc, TaiGen Biotechnology Co. Ltd, Aridis Pharmaceuticals Inc., Tergene Biotech Limited.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/pneumonia-therapeutics-global-market-report

Which Region Is Forecasted To Lead The Pneumonia Therapeutics Market In The Coming Years?

North America was the largest region in the pneumonia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumonia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21258&type=smp

Browse Through More Reports Similar to the Global Pneumonia Therapeutics Market 2025, By The Business Research Company

Anti Asthmatics And Copd Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

Asthma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model